Free Trial

BioXcel Therapeutics (BTAI) News Today

BioXcel Therapeutics logo
$0.59 -0.01 (-1.67%)
(As of 11/20/2024 ET)
BioXcel Therapeutics Reports Q3 2024 Financial Results
BioXcel Therapeutics advances Phase 3 trials of BXCL501
BioXcel Therapeutics to Present at ThinkEquity Conference
BioXcel Therapeutics executive sells shares worth $238
BioXcel Therapeutics Inc (BX2.BE)
BioXcel Therapeutics Reports Second Quarter 2024 Financial Results
BioXcel Therapeutics, Inc. stock logo
Short Interest in BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Rises By 8.7%
BioXcel Therapeutics, Inc. (NASDAQ:BTAI - Get Free Report) was the recipient of a significant growth in short interest in June. As of June 30th, there was short interest totalling 1,620,000 shares, a growth of 8.7% from the June 15th total of 1,490,000 shares. Based on an average trading volume of 588,800 shares, the days-to-cover ratio is presently 2.8 days.
BioXcel Therapeutics, Inc. stock logo
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Given Average Rating of "Hold" by Brokerages
Shares of BioXcel Therapeutics, Inc. (NASDAQ:BTAI - Get Free Report) have been given an average recommendation of "Hold" by the seven brokerages that are presently covering the stock, Marketbeat reports. Four analysts have rated the stock with a hold recommendation and three have assigned a buy re
BioXcel Therapeutics, Inc. stock logo
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) CEO Vimal Mehta Sells 126,014 Shares
BioXcel Therapeutics, Inc. (NASDAQ:BTAI - Get Free Report) CEO Vimal Mehta sold 126,014 shares of the stock in a transaction that occurred on Tuesday, June 4th. The stock was sold at an average price of $1.63, for a total value of $205,402.82. Following the transaction, the chief executive officer now owns 7,811,515 shares in the company, valued at $12,732,769.45. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
BioXcel Therapeutics, Inc. stock logo
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Short Interest Up 8.7% in May
BioXcel Therapeutics, Inc. (NASDAQ:BTAI - Get Free Report) was the recipient of a significant growth in short interest in May. As of May 15th, there was short interest totalling 1,630,000 shares, a growth of 8.7% from the April 30th total of 1,500,000 shares. Based on an average trading volume of 584,400 shares, the days-to-cover ratio is presently 2.8 days.
BioXcel Therapeutics, Inc. stock logo
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Short Interest Update
BioXcel Therapeutics, Inc. (NASDAQ:BTAI - Get Free Report) was the recipient of a significant decrease in short interest in the month of April. As of April 30th, there was short interest totalling 1,500,000 shares, a decrease of 28.2% from the April 15th total of 2,090,000 shares. Based on an average trading volume of 1,440,000 shares, the short-interest ratio is currently 1.0 days.
BioXcel Therapeutics, Inc. stock logo
BioXcel Therapeutics (NASDAQ:BTAI) Releases Earnings Results, Misses Expectations By $0.19 EPS
BioXcel Therapeutics (NASDAQ:BTAI - Get Free Report) announced its earnings results on Thursday. The company reported ($0.87) earnings per share for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.19). BioXcel Therapeutics had a negative return on equity of 890.63% and a negative net margin of 12,974.86%. The company had revenue of $0.58 million during the quarter, compared to the consensus estimate of $0.42 million. During the same period in the prior year, the firm posted ($1.84) earnings per share.
Q1 2024 BioXcel Therapeutics Inc Earnings Call
BioXcel Therapeutics, Inc. stock logo
Short Interest in BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Declines By 16.1%
BioXcel Therapeutics, Inc. (NASDAQ:BTAI - Get Free Report) was the recipient of a large decline in short interest during the month of April. As of April 15th, there was short interest totalling 2,090,000 shares, a decline of 16.1% from the March 31st total of 2,490,000 shares. Based on an average daily volume of 1,510,000 shares, the short-interest ratio is presently 1.4 days.
BioXcel Therapeutics, Inc. stock logo
Q1 2024 EPS Estimates for BioXcel Therapeutics, Inc. Lifted by HC Wainwright (NASDAQ:BTAI)
BioXcel Therapeutics, Inc. (NASDAQ:BTAI - Free Report) - HC Wainwright boosted their Q1 2024 earnings per share estimates for shares of BioXcel Therapeutics in a report released on Monday, April 15th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn ($0.69) per share
Get BioXcel Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for BTAI and its competitors with MarketBeat's FREE daily newsletter.

Trump said you could learn something from this man (Ad)

Early Warning: A Deep Crack Is Forming In The US Economy Stocks are booming thanks to Trump’s landslide victory. Yet one former Trump advisor says the picture is less rosy than it seems. “I’ve found a deep crack forming in the foundations of the US economy,” he says. “And before too long, it could tear our country apart.” It’s critical you learn more today, BEFORE it impacts your money and your retirement.

Here’s everything you need to know.

BTAI Media Mentions By Week

BTAI Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

BTAI
News Sentiment

0.25

0.45

Average
Medical
News Sentiment

BTAI News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

BTAI Articles
This Week

4

2

BTAI Articles
Average Week

Get BioXcel Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for BTAI and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:BTAI) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners